Abstract Sodium glucose cotransporter-2 (SGLT2) inhibitors improve cardiorenal outcomes
in patients with type 2 diabetes mellitus, chronic kidney disease, and chronic heart failure …

With worsening epidemiological trends for both the incidence and prevalence of type 2
diabetes mellitus (T2DM) and heart failure (HF) worldwide, it is critical to implement optimal …

Importance Recent randomized clinical trials have demonstrated that glucagon-like peptide-
1 receptor agonists (GLP-1RAs) reduce cardiovascular events in at-risk individuals with type …

Objectives The purpose of this study was to characterize the clinical profile, treatment
patterns, and clinical outcomes of patients with comorbid diabetes mellitus (DM) and heart …

Importance Heart failure (HF) incidence is declining among Medicare beneficiaries.
However, the epidemiological mechanisms underlying this decline are not well understood …

Background Several new classes of glucose-lowering medications have been introduced in
the past two decades. Some, such as sodium-glucose cotransporter 2 inhibitors (SGLT2s) …

Background The rapidly increased spending on insulin is a major public health issue in the
United States. Industry marketing might be one of the upstream determinants of physicians' …

Aim To evaluate the effects of empagliflozin versus placebo on subsequent insulin initiation
or dosing changes in a large cardiovascular outcomes trial. Materials and Methods In EMPA …

Methods| We reviewed 6 drug classes using first quarter 2019 Medicare formulary and
pricing files, which contain drug prices and cost sharing for all Part D plans, including stand …

Objective: The objective of this study was to describe national changes in utilization and
associated costs of antidiabetic medications in the United States from 2014 to 2019, across …